The Potential Application of Zoledronic Acid as Anticancer Therapy in Patients With Non–Small-Cell Lung Cancer
- 1 January 2011
- journal article
- review article
- Published by Elsevier BV in Clinical Lung Cancer
- Vol. 12 (1), 26-32
- https://doi.org/10.3816/clc.2011.n.003
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Bisphosphonate Use in Patients with Lung Cancer and Bone Metastases: Recommendations of a European Expert PanelJournal of Thoracic Oncology, 2009
- Skeletal Disease Contributes Substantially to Morbidity and Mortality in Patients with Lung CancerClinical Lung Cancer, 2009
- Bone marrow micrometastases in advanced stage non-small cell lung carcinoma patientsLung Cancer, 2008
- Zoledronic acid and skeletal complications in patients with solid tumors and bone metastasesCancer, 2008
- Skeletal metastases in non-small cell lung cancer: A retrospective studyLung Cancer, 2007
- Detection of MAGE-A Transcripts in Bone Marrow Is an Independent Prognostic Factor in Operable Non–Small-Cell Lung CancerClinical Cancer Research, 2007
- Long‐term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumorsCancer, 2004
- Metastasis to bone: causes, consequences and therapeutic opportunitiesNature Reviews Cancer, 2002
- Micrometastases in non-small cell lung cancer (NSCLC)Lung Cancer, 2001
- Nitrogen-Containing Bisphosphonates Inhibit Isopentenyl Pyrophosphate Isomerase/Farnesyl Pyrophosphate Synthase Activity with Relative Potencies Corresponding to Their Antiresorptive Potenciesin Vitroandin VivoBiochemical and Biophysical Research Communications, 1999